Skip to content
Screener

Supernus Pharmaceuticals SUPN Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$207.7MBeat by $14.8M
EPS$0.59Beat by $0.31
Revenue estimate$192.9M
EPS estimate$0.28

Next report

Nov 3, 2026 (in a month)
Revenue estimate$218.3M
EPS estimate$0.62

Financials

Q1 2026

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.98B+62.8%
Enterprise value$2.83B+62.3%
P/S3.8×+1.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Segments

By product

See full
Qelbree$77.8M+20.2%
GOCOVRI$35.2M+14.8%
Royalty, licensing, and other revenues$29.3M+274%
Collaboration revenue (ZURZUVAE)$27.6M—
Trokendi XR$9.5M-26.0%

By segment

See full
Reportable Segment$207.7M+38.6%

FAQ

When did Supernus Pharmaceuticals report Q1 2026 earnings?
Supernus Pharmaceuticals (SUPN) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Supernus Pharmaceuticals's Q1 2026 revenue and EPS?
Supernus Pharmaceuticals reported revenue of $207.7M and eps of $0.59 for Q1 2026.
Did Supernus Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $192.9M by $14.8M. EPS beat the consensus estimate of $0.28 by $0.31.
How did Supernus Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 38.6% from $149.8M a year earlier and eps grew 40.5% from $0.42.
Where can I find Supernus Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001356576-26-000020) and the 10-Q periodic report (0001356576-26-000022) directly on SEC EDGAR. The filing index links above go to sec.gov.